(Q38053680)

27 August 2017

Targeting angiogenesis as a promising modality for the treatment of prostate cancer (English)

1 reference

27 August 2017

Jianqing Lin

1

1 reference

PubMed ID

23084530

27 August 2017

William K Kelly

series ordinal

2

1 reference

27 August 2017

1 November 2012

1 reference

Urologic Clinics of North America

27 August 2017

1 reference

27 August 2017

39

1 reference

27 August 2017

4

1 reference

27 August 2017

547-560

1 reference

Tumor angiogenesis: therapeutic implications

27 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Angiogenesis-dependent diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Tumorigenesis and the angiogenic switch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Angiogenesis in cancer and other diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Molecular mechanisms and clinical applications of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Angiogenesis inhibitors: current strategies and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Hypoxic regions exist in human prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Targeting HIF-1 for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Hypoxia-inducible factor-1 in human breast and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Clinical implications of circulating angiogenic factors in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Expression of vascular endothelial growth factor receptors in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Roles of heparan-sulphate glycosaminoglycans in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

High interstitial fluid pressure - an obstacle in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Angiogenesis as a therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Angiogenesis and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Thalidomide is an inhibitor of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Phase II study of sunitinib in men with advanced prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.010

10.1016/J.UCL.2012.07.010

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

23084530